Efficacy News and Research

RSS

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has approved BENLYSTA® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

10 Mar 2011

KineMed extends collaboration with BMY to identify and characterize Alzheimer's biomarkers

KineMed, Inc. announced today the extension of its collaboration with Bristol-Myers Squibb in the area of Alzheimer's disease and other neurodegenerative conditions.

9 Mar 2011

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

NeuroDerm, Ltd. announced today the enrollment of the first group of patients in its Phase I/II clinical trial of ND0611, a new patch for the treatment of Parkinson's disease.

9 Mar 2011

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

ERYtech Pharma announces the early completion of the enrollment and safety follow-up a Phase II clinical trial for GRASPA. This open-labeled trial introduced GRASPA in a first-line treatment for Acute Lymphoblastic Leukemia in patients older than 55 years.

9 Mar 2011

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Adamis Pharmaceuticals Corporation announced today that it has recently submitted to the FDA an Investigational New Drug application for APC-100 to treat prostate cancer.

9 Mar 2011

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

Vertex Pharmaceuticals Incorporated announced today that 15 abstracts on the company's medicines in development for hepatitis C, including its protease inhibitor, telaprevir, and polymerase inhibitor, VX-222, were accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver in Berlin, Germany, March 30 to April 3, 2011.

9 Mar 2011

'Cross-talk' between two major biological pathways may hold a clue for chronic pain treatment

Researchers at the University of California, Davis have discovered a "cross-talk" between two major biological pathways that involve pain-research that may pave the way to new approaches to understanding and controlling chronic pain.

9 Mar 2011

ITMNs can reduce Japanese Encephalitis transmission to humans

A new study revealed that using treated mosquito nets could drastically reduce the transmission of Japanese Encephalitis to humans.

9 Mar 2011

Unique gene therapy to combat Parkinson's disease

Physicians at Rush University Medical Center are testing a unique gene therapy product called CERE-120 to evaluate if its use can improve the symptoms of Parkinson's disease. Rush is one of 11 sites in the U.S. and the only site in Illinois enrolling patients into the new, double-blinded trial.

9 Mar 2011

Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

An advisory committee recommended today that the Food and Drug Administration (FDA) approve QAB149 (indacaterol) 75 mcg in the US as a once-daily long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

9 Mar 2011

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Plexxikon today announced that it has treated the first patient in a Phase 2 clinical trial in Hodgkin lymphoma with PLX3397. This novel agent is an oral, selective inhibitor that down-modulates two key cell types that are thought to mediate the progression of Hodgkin lymphoma tumors — macrophages and mast cells.

8 Mar 2011

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

Patrys Limited (ASX: PAB), which is developing a new class of antibody molecules for the treatment of cancer, is pleased to announce success in obtaining commercial production yields for natural human antibody PAT-SC1, facilitating the advancement of this promising product toward a second human clinical trial for the treatment of cancer.

8 Mar 2011

Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA

A recent trial of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis found the safety profile to be consistent with other RA trials with TNF inhibitors.

8 Mar 2011

Vertos reports long-term safety and efficacy of mild in patients with LSS

Medical device company Vertos Medical Inc. has announced the release of clinical study data demonstrating the long-term safety and efficacy of mild as well as its superior durability over epidural steroid injections for treating lumbar spinal stenosis.

8 Mar 2011

Mississippi researchers work on drug discovey for poison ivy skin rash

Each year nearly 50 million Americans develop an annoying skin rash after coming in contact with poison ivy. But University of Mississippi researchers are working on a pharmaceutical product to rein in the allergic reaction in people already sensitive to the plants and prevent it altogether in those who aren't.

8 Mar 2011

Aerie Pharmaceuticals closes $30 million Series B financing

Aerie Pharmaceuticals, Inc, a biotechnology company focused on the discovery and development of medical innovations in ophthalmology, today announced the closing of a $30 million Series B financing.

7 Mar 2011

Hadasit, Yissum license innovative regenerative membrane implant to RegeneCure

Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, and Hadasit Medical Research Services & Development Ltd., the technology transfer company of the Hadassah University Medical Center, today announced that they have licensed innovative regenerative membrane implant technology to RegeneCure, which will further develop and commercialize the technology for bone tissue engineering for applications in trauma, spine, and reconstructive cranial and facial orthopedics.

7 Mar 2011

Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

ZIOPHARM Oncology, Inc., an oncology small molecule and synthetic biology drug development company, and Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today that they have entered into a license and collaboration agreement to develop and commercialize ZIOPHARM's darinaparsin product and related organic arsenic molecules in specified Pan-Asian/Pacific territories.

7 Mar 2011

Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it is initiating a Phase II clinical trial for its VGX-3100 DNA vaccine for cervical dysplasia and cancer caused by human papillomavirus.

7 Mar 2011

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics.

7 Mar 2011

Efficacy News and Research

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

KineMed extends collaboration with BMY to identify and characterize Alzheimer's biomarkers

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

'Cross-talk' between two major biological pathways may hold a clue for chronic pain treatment

ITMNs can reduce Japanese Encephalitis transmission to humans

Unique gene therapy to combat Parkinson's disease

Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA

Vertos reports long-term safety and efficacy of mild in patients with LSS

Mississippi researchers work on drug discovey for poison ivy skin rash

Aerie Pharmaceuticals closes $30 million Series B financing

Hadasit, Yissum license innovative regenerative membrane implant to RegeneCure

Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

Inovio initiates VGX-3100 Phase II trial in patients with cervical cancer

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News